buy metformin online
PT Jyothi Datta Mumbai, December 22, Armed patent in the U.S. for its improved version of the kidney medicine, sevelamer, Rs 1020 crore drug maker, USV, to assess its capacity to take the product further. "This broad patent covering a wide range of manufacturing processes, and the company now" want to monetize the IP (intellectual property), "USV Managing Director, Mr. Prashant Tewari, told Business Line. This Mumbai-based company accounts for 17 {+ T} {+ H} patent in the U.S. and it is weighing whether to sell its version of the drug itself or license it to companies who might be interested in selling drugs, he said. Phosphate-bindidng originally sold under the brand name of Renagel Genzyme (NASDAQ: GENZ) Inc Cambridge (Mass.), renal drugs, when taken with food, helps to bind with dietary phosphate, preventing its absorption. Patients with chronic renal failure to use the phosphate-binding medication to prevent hyper-phosphatemia, a condition in which phosphates are high, which may lead to kidney damage. And USV has developed a way to make sevelamer significantly more powerful by increasing its phosphate-binding capacity, explains the report by America's pharmaceutical patent attorneys. "U.S. Patent Office reviewed the study and found it quite enough to merit a patent, U.S. Patent Office awarded a patent as a result of this month," said the note. It is noteworthy that the last patent USV, apparently to pre-empt competitive work of Israeli pharmaceutical company, Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA), note added. The original drug was tainted income of about $ 600 million and the product patent on the drug expires in 2014. But there are problems in the generic drug of seeking patents invalid innovator, and if they win, the general-like version of the drug could be on the market before, Mr. Tewari said. Internal study, Dr. Mark Paul, one of the lawyers in the case, explained that the last patent was the result of internal investigations USV, and is not related to the earlier patent, which he received from CSIR (Council for Scientific and Industrial Research) for the active ingredient. USV allocates about 7 percent of its revenues on research and consists of seven products approved in the U.S., said Mr Tewari. The company sells in the U.S. through Indicus Pharma, where it owns about 90 percent. Optimistic about the prospects for the Indian market, USV - touted to be the largest country on an oral anti-diabetic products company - hopes to strengthen its diabetes product portfolio by bringing in India, diabetes products belonging to other companies. USV has an existing joint marketing tie-up with Novartis (NYSE: NVS), to sell anti-diabetes Galvus latest product in India. .
Sponsor: Chongqing Medical University : Collaborators: Fuling Central Hospital Three Gorges Central Hospital: Information provided by: Chongqing Medical University. Study Status: This study is currently recruiting participants. Estimated Study Completion Date: December 2013 Estimated Primary Completion Date:. The investigators designed this prospective, randomized control study to compare the ef . Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes The investigators designed this prospective, randomized control study to . Sponsor: Chongqing Medical University : Collaborators: Fuling Central Hospital Three Gorges Central Hospital: Information provided by: Chongqing Medical University. Study Status: This study is currently recruiting participants. Estimated Study Completion Date: December 2013 Estimated Primary Completion Date:. The investigators designed this prospective, randomized control study to compare the ef . Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes The investigators designed this prospective, randomized control study to .
Moms-to-be need for early warning of diabetes - National

Moms-to-be need for early warning of diabetes - National
Moms-to-be need for early warning of diabetes - National

Moms-to-be need for early warning of diabetes - National
Moms-to-be need for early warning of diabetes - National

Respiratory drugs increases the risk of diabetes - MedPage Today

Moms-to-be need for early warning of diabetes - National
Generex announces the publication of new positive Generex Oral-Lyn в„ў data to Peer ... - PR Newswire (press release)
Moms-to-be need for early warning of diabetes - National
How to think about the treatment of diabetes mellitus: Part 2 - AOL Health
USV looks monetization of U.S. patent for a kidney drug - istockAnalyst.com (press release)
Respiratory drugs increases the risk of diabetes - MedPage Today
Moms-to-be need for early warning of diabetes - National